The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: An update

Mass Spectrometry Reviews

Volumn 25, Issue 5, 2006, Pages 775-797

  Lapolla, Annunziata ^a   Fedele, Domenico ^a   Seraglla, Roberta ^b   Traldi, Pietro ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

Advanced glycation end products (AGEs); AGE peptides; Diabetes; End stage renal disease; Mass spectrometry; Non enzymatic glycation

Indexed keywords

ALDEHYDES; BODY FLUIDS; ENZYME KINETICS; HYDROLYSIS; KETONES; MASS SPECTROMETERS; MEDICAL PROBLEMS; METABOLISM; POLYPEPTIDES;

ADVANCED GLYCATION END PRODUCTS (AGES); AGE PEPTIDES; DIABETES; END STAGE RENAL DISEASE; NON-ENZYMATIC GLYCATION;

PROTEINS;

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; ENZYME; PLASMA PROTEIN;

BLOOD; CHEMISTRY; DIABETES MELLITUS; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; REVIEW;

BIOLOGICAL MARKERS; BLOOD PROTEINS; DIABETES MELLITUS; ENZYMES; GLYCOSYLATION END PRODUCTS, ADVANCED; MASS SPECTROMETRY;

EID: 33748292943     PISSN: 02777037     EISSN: None     Source Type: Journal    
DOI: 10.1002/mas.20090     Document Type: Review

References (60)

1. Ahmed N, Argirov OK, Minhas HS, Cordeiro A, Thornalley PJ. 2002. Assay of advanced glycation endproducts (AGEs): Surveing AGE's by Chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidil-carbamate and application to Nε-carboxymethyllysine and Nε-(1-carboxyethyl)lysine modified albumin. Biochem J 364:1-14.
2. Ahmed N, Babei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. 2005a. Degradation products of protein damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590-1603.
3. Ahmed N, Dobler D, Dean M, Thornalley PJ. 2005b. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280:5724-5732.
4. Brock JW, Hinton DJS, Cotham WE, Metz TO, Thorpe SR, Baynes JW, Ames JM. 2003. Proteomic analysis of the site specificity of glycation and carboxymethylation of ribonuclease. J Proteome Res 2:506-513.
5. Brown W, Wold F. 1973. Alkyl isocyanates as active-site-specific reagents for serine protease. Reaction properties. Biochemistry 12:828-834.
6. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820.
7. Bucala R, Makita Z, Vega G, Grundy S, Koshinsky T, Cerami A, Vlassara H. 1994. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445.
8. Cerami A. 1994. The role of the Maillard reaction in vivo in Maillard reaction in chemistry, food and healthy. In: Labuza TP, Reineccius GA, Monnier VM, O'Brien J, Baynes JW, editors. The Royal Society of Chemistry, Cambridge, pp 1-10.
9. Combet S, Miyata T, Moulin PV. 2000. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 11:717-728.
10. Cotham WE, Hinton DJ, Metz TO, Brock JW, Thorpe SR, Baynes JW, Ames JM. 2003. Mass spectrometric analysis of glucose-modified ribonuclease. Biochem Soc Trans 31:1426-1427.
11. Cotham WE, Metz TO, Ferguson PL, Brock JW, Hinton DJ, Thorpe SR, Baynes JW, Ames JM. 2004. Proteomic analysis of arginine adducts on glyoxal-modified ribonuclease. Moll Cell Proteomics 3:1145-1153.
12. Dean RT. 1975. Lysosomal enzymes as agents of turnover of soluble cytoplasmic protein. Eur J Biochem 58:9-14.
13. Gerdemann A, Lemke HD, Heidland A, Munch G, Bahner U, Schinzel R. 2000. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 54:276-283.
14. Gugliucci A, Bendayan M. 1996. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 39:149-160.
15. Gugliucci A, Menini T. 1998. Circulating advanced glycation peptides in streptozotocin-induced diabetic rats: Evidence for preferential modification of IgG light chains. Life Sci 62:2141-2150.
16. Hillenkamp F, Karas M, Beavis RC, Chait BT. 1991. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal Chem 63:1193A-1203A.
17. Horiuchi S, Higashi T, Ikeda K, Saishoji T, Jinnouchi Y, Sano H, Shibayama R, Sakamoto T, Araki N. 1996. Advanced glycation end products and their recognition by macrophage and macrophage-derived cells. Diabetes 45(Suppl 3):S73-S76.
18. Humeny A, Kislinger T, Becher CM, Pischetsrieder M. 2002. Qualitative determination of specific protein glycation products by matrix-assisted laser desorption mass spectrometry peptide mapping. J Agric Food Chem 50:2153-2160.
19. Kennedy DM, Skillen AW, Self GH. 1994. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 98:245-256.
20. Kislinger T, Humeny A, Peich CC, Backer CM, Pischetsrieder M. 2005. Analysis of protein glycation products by MALDI-TOF/MS. Ann NY Acad Sci 1043:249-259.
21. Korbert SM, Makita Z, Firanek CA, Vlassara H. 1993. Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 22:588-591.
22. Krediet RT. 1998. Prevention and treatment of peritoneal dialysis membrane failure. Adv Ren Replace Ther 5:212-217.
23. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, Suzuki K, Miyazaki H, Yamashita Y, Inaba K, Kasuga M. 2003. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 26:1889-1894.
24. Lapolla A, Fedele D, Aronica R, Garbeglio M, D'Alpaos M, Seraglia R, Traldi P. 1997. Evaluation of IgG glycation levels by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 11:1342-1346.
25. Lapolla A, Fedele D, Aronica R, Baldo L, D'Alpaos M, Seraglia R, Traldi P. 1996. The in vitro glycation of lysozyme and the influence of the buffer concentration investigated by mass spectrometry. Rapid Commun Mass Spectrom 10:1512-1518.
26. Lapolla A, Fedele D, Garbeglio M, Martano L, Tonani R, Seraglia R, Favretto D, Fedrigo MA, Traldi P. 2000a. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of non-enzymatic glycation of IgG. J Am Soc Mass Spectrom 11:153-159.
27. Lapolla A, Fedele D, Martano L, Aricò NC, Garbeglio M, Traldi P, Seraglia R, Favretto D. 2001. Advanced glycation end products: A higly complex set of biologically relevant compounds detected by mass spectrometry. J Mass Spectrom 36:370-378.
28. Lapolla A, Fedele D, Reitano R, Aricò NC, Seraglia R, Traldi P, Marotta E, Tonani R. 2004. Enzymatic digestion and mass spectrometry in the study of advanced glycation end products/peptides. J Am Soc Mass Spectrom 15:496-509.
29. Lapolla A, Fedele D, Reitano R, Bonfante L, Pastori G, Seraglia R, Tubaro M, Traldi P. 2005. Advanced glycation end products/peptides: An in vivo investigation. Ann NY Acad Sci 1043:1-9.
30. Lapolla A, Fedele D, Senesi A, Aricò NC, Reitano R, Favretto D, Seraglia R, Astner H, Traldi P. 2002a. Advanced glycation end-products/peptides: A preliminary investigation by LC and LC/MS. II Farmaco 57:845-852.
31. Lapolla A, Fedele D, Traldi P. 2000. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes. Mass Spectrom Rev 19:279-304.
32. Lapolla A, Flamini R, Dalla Vedova A, Senesi A, Reitano R, Fedele D, Basso E, Seraglia R, Traldi P. 2003a. Glyoxal and methyl-glyoxal in diabetic patients: Quantitative determination by a new GC/MS method. Clin Chem Lab Med 41:1166-1173.
33. Lapolla A, Flamini R, Lupo A, Aricò NC, Rugiu C, Reitano R, Tubaro M, Ragazzi E, Seraglia R, Traldi P. 2005a. Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis. Ann NY Acad Sci 1043:1-9.
34. Lapolla A, Flamini R, Tonus T, Fedele D, Senesi A, Reitano R, Marotta E, Pace G, Seraglia R, Traldi P. 2003. An effective derivatization methodv for quantitative determination of glyoxal and methyl-glyoxal in plasma samples by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 17:876-878.
35. Lapolla A, Tonani R, Fedele D, Garbeglio M, Senesi A, Seraglia R, Favretto D, Traldi P. 2002. Non-enzymatic glycation of IgG: An in vivo study. Horm Met Res 34:260-264.
36. Makita Z, Bucala R, Rayfield ES, Freidmann EA, Kaufman AM, Korbert SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. 1994. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522.
37. Makita Z, Radoff S, Raifield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. 1991. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842.
38. Makita Z, Vlassara H, Cerami A, Bucala R. 1992. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138.
39. Marotta E, Lapolla A, Fedele D, Senesi A, Reitano R, Witt M, Seraglia R, Traldi P. 2003. Accurate mass measurements by Fourier transform mass spectrometry in the study of advanced glycation end products/peptides. J Mass Spectrom 38:196-205.
40. McLellan AC, Phillips SA, Thornalley PJ. 1992. The assay of methylglyoxal in biological system by derivatization with 1,2-diamino-4,5-dimethoxybenzene. Anal Biochem 206:17-23.
41. Miyata T, Fu MX, Kurokawa K, van Ypersele De Strihou C, Thorpe SR, Baynes JW. 1998. Products of autoxidation of both carbohydrates and lipids are increased in uremic plasma: Evidence for a generalized increase in oxidative stress in uremia? Kidney Int 54:1290-1295.
42. Miyata T, Hori O, Yan S, Ferran L, Iida Y, Schmidt A. 1996. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloid. J Clin Invest 98:1088-1094.
43. Miyata T, van Ypersele de Strithou C, Thorpe S, Bayness JW. 1999. Alteration in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long term uremic complications. Kidney Int 55:389-399.
44. Monnier VM, Sell DR, Miyata S, Nagaraj RH, Odetti P, Lapolla A. 1992. Advanced Maillard reaction products as a marker for tissue damage in diabetes and uremia: Relevance to diabetic nephropathy. Acta Diabetol 29:130-135.
45. Nilsson-Thorell CB, Muscalu N, Andren AHG, Kjellstrand PTT, Wieslander AP. 1993. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Pent Dial Int 13:208-213.
46. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. 1999. Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: Specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun 256:89-93.
47. Odani H, Shinzato T, Usami J, Matsumoto Y, Brinkmann Frye E, Baynes JW, Maeda K. 1998. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: Evidence for increased oxidative stress in uremia. FEBS Lett 427:381-385.
48. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. 1994. Immunological quantification of advanced glycosylation endproducts in the serum of patients on haemodialysis or CAPD. Kidney Int 46:216-222.
49. Raj DSC, Choudhury D, Welbourne TC, Levi M. 2000. Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 35:365-380.
50. Ritz E, Deppisch R, Nawroth P. 1994. Toxicity of uraemia: Does it come of AGE?. Nephrol Dial Transplant 9:1-2.
51. Schalkwijk CG, Posthuna M, ten Brink HJ, ter Wee PM, Teerlink T. 1999. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 19:325-333.
52. Sharp PS, Rainbow S, Mukherjee S. 2003. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 20:575-579.
53. Sing R, Barden A, Mori T, Beilin L. 2001. Advanced glycation end-products: A review. Diabetologia 44:129-146.
54. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirkstein M, Vlassara H. 1991. Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174:931-939.
55. Thornalley PJ, Langborg A, Minhas HS. 1999. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116.
56. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. 2003. Qualitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581-592.
57. Thornalley PJ. 1996. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 3:149-166.
58. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, Izuhara Y, Saito A, Kurokawa K, Van Ypersele De Strihou C. 2000. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 58(6):2518-2524.
59. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E. 2003. Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298-305.
60. Zilin S, Naifeng L, Bicheng L, Jiping W. 2001. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta 313:69-75.